Compounds 1 （C17H22N2,Mr =254.37） and 2 （C13H16N2,Mr=200.28） have been synthesized and their crystal structures were determined by single-crystal X-ray diffraction.Crystal 1 belongs to triclinic,space group P（1） with a =6.524（2）,b =8.987（3）,c =12.746（5） A,α =95.220（7）,β =90.055（6）,γ =104.431（6）°,V =720.5（4） A^3,Z =2,Dc =1.173 g/cm^3,μ（MoKα） =0.069 mm1,F（000） =276,R =0.0578 and wR =0.1221 for 1487 observed reflections Ⅰ 〉 2o（Ⅰ）.Crystal 2 is of tetragonal system,space group Ⅰ41/a with a =20.763（10）,b =20.763（10）,c =11.427（6） A,V=4926（4） A3,Z =16,Dc =1.080 g/cm^3,μ（MoKα） =0.065 mm-1,F（000） =1728,R =0.0581 and wR =0.1288 for 1408 observed reflections with Ⅰ 〉 2σ（Ⅰ）.Although the two compounds are similar with the same pyrazole and benzene ring units,X-ray analysis reveals that their structures are completely different maybe caused by steric effects.
The new title compound 8-（（4-（（2,3-diaminopyridin-4-yl）-oxy）-3-fluorophenyl）-amino）-2-（4-fluorophenyl）-3-methyl-2,7-naphthyridin-1（2H）-one（C26H20F2N6O2, Mr = 486.48） has been prepared and determined by single-crystal X-ray diffraction. The crystal is of monoclinic, space group P21/c with a = 15.365（3）, b = 13.144（2）, c = 11.863（2）, β= 108.882（3）°, Z = 4, V = 2267.0（7）3, Dc = 1.425 g/cm3, F（000） = 1008, μ = 0.105 mm-1, MoKa radiation（λ = 0.71073）, R = 0.0480 and wR = 0.1294 for 3197 observed reflections with I 〉 2σ（I）. X-ray diffraction analysis reveals that the region C（substituents of 8-amino group and 3-methyl group on the 2,7-naphthyridin-1（2H）-one ring） of compound 6 are effectively planar. Intramolecular and intermolecular hydrogen bonds together with π···π interations are found in the structure. In addition, compound 6 shows potent c-Met and c-Kit kinase inhibition activities.
A new compound [C19H19N3O3F2Cl·C4H3O4·H2O]（I）,（7-（（7S）-7-aminospiro[2.4]heptan-5-yl）-8-chloro-6-fluoro-1-（（1R,2S）-2-fluorocyclopropyl）-4-oxo-1,4-dihydroquinoline-3-carboxylic acid fumaric acid monohydrate）, was synthesized and structurally characterized by single-crystal X-ray diffraction, ^1H NMR, 14 C spectra and mass spectra. I crystallizes in monoclinic, space group P21/c with a = 8.495（2）, b = 12.545（3）, c = 11.832（3） A, β = 103.37（1）°, V = 1226.8（5） A^3, Z = 2, Mr = 543.90, Dc = 1.472 g/cm^3, F（000） = 564, μ = 0.225 mm^-1, the final R = 0.0307 and wR = 0.0892 for 6886 observed reflections with I 〉 2σ（I）. X-ray diffraction analysis reveals that the quinolinone ring is almost coplanar, and the pyrrole ring adopts an envelope form. Packing of crystal I is constructed and stabilized by the N–H…O, O–H…O and N–H…Cl hydrogen bonds together with C–H…π interations.
Compounds 1 （C15H17C1F3N303, Mr = 379） and 2 （C14H14C1F3N4OS, Mr = 378） have been synthesized and their crystal structures were determined by single-crystal X-ray diffraction. Crystal 1 belongs to the triclinic system, space group P1 with a = 6.0223（19）, b = 9.324（3）, c = 15.936（5） A, a = 80.687（5）, β= 87.289（5）, ）, = 86.097（5）°, V= 880.4（5） A3, Z = 2, Dc = 1.433 g/cm3,μ（MoKa） = 0.266 mm^-1, F（000） = 392, R = 0.0861 and wR = 0.1999 for 2022 observed reflections with I 〉 2o（/）. Crystal 2 belongs to the triclinic system, space group PI with a = 7.7029（15）, b = 8.3371（16）, c = 14.410（3） A, a = 100.672（3）, β= 103.168（3）, ？ = 98.726（3）°, V = 876.1（3） A3, Z = 2, Dc= 1.451 g/cm^3,μ（MoKa） = 0.379 mm^-1, F（000） = 388, R = 0.0672 and wR = 0.2105 for 2725 observed reflections with I 〉 2σ（I）. Although the two compounds are similar with the same pyrazole and pyrethroid units, X-ray analysis reveals that their structures are completely different.
